Building on our expertise in gene editing (CRISPR, base editing, and epigenetic modification), NZCR was proud to be involved in a recent encouraging Intellia Therapeutics study into hereditary angioedema.
NZCR has been involved in over 10 gene editing studies to date, including The UNIVERSE study. This Phase 1 and 2 study involved 14 NZCR participants – a significant portion of the total worldwide cohort of participants in these 2 phases.
New England Journal of Medicine reported:
NTLA-2002, administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema. These results support continued investigation in a larger phase 3 trial.
Our very own Hilary Longhurst (Trial Principal Investigator) and Karen Lindsay (Sub-Investigator) are contributors to the article.
Read more about this novel study in the New England Journal of Medicine:
NZCR is New Zealand’s largest early-phase clinical trials company with over 800 successful trials across a variety of specialties and we are delighted to help pharmaceutical companies worldwide in the growing area of CRISPR and other gene editing techniques.
